Raymond James Financial
SUPN icon

Raymond James Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Raymond James Financial’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.69M Buy
143,857
+18,564
+15% +$892K ﹤0.01% 2506
2026
Q1 		$6.48M Buy
125,293
+36,335
+41% +$1.85M ﹤0.01% 2384
2025
Q4 		$4.42M Buy
+88,958
New +$4.33M ﹤0.01% 2620
2025
Q3 		– Sell
-1,756
Closed -$55.3K – 6564
2025
Q2 		$55.3K Buy
+1,756
New +$56.3K ﹤0.01% 5144
2025
Q1 		– Sell
-189,364
Closed -$6.85M – 4945
2024
Q4 		$6.85M Buy
+189,364
New +$6.67M ﹤0.01% 2113

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Raymond James Financial's SUPN Position: Q2 2026 in Review

Raymond James Financial increased its Supernus Pharmaceuticals (SUPN) stake by 15% in Q2 2026, buying an estimated $892K and bringing the position to 143,857 shares worth $6.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2506.

Raymond James Financial first reported a position in SUPN in Q4 2024 and has held it in 5 quarters since. The position peaked at $6.85M in Q4 2024. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Raymond James Financial held 143,857 shares of Supernus Pharmaceuticals worth $6.69M as of Q2 2026.
  • Raymond James Financial bought 18,564 Supernus Pharmaceuticals shares in Q2 2026, an estimated $892K.
  • Supernus Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2506 holding.
  • Raymond James Financial first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 5 quarters since.
  • Raymond James Financial's Supernus Pharmaceuticals position peaked at $6.85M in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.